Literature DB >> 2984943

Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat.

K Kitani, M Ohta, S Kanai.   

Abstract

Biliary excretion of various proteins (5'-nucleotidase, alkaline phosphatase, lactate dehydrogenase, and albumin) was investigated in pentobarbital sodium-anesthetized rats infused with different bile salts [taurocholate (TC), taurochenodeoxycholate (TCDC), and tauroursodeoxycholate (TUDC)]. A TCDC infusion at 0.4 mumol . min-1 . 100 g body wt-1 caused much higher increases in the biliary excretion of these proteins compared with the respective values in rats that received an infusion of TC at a threefold higher rate (1.2 mumol . min-1 . 100 g body wt-1). In contrast, a TUDC infusion at 1.8 mumol . min-1 . 100 g body wt-1 showed the minimum effect on these protein leakages. A combined infusion of TCDC (0.4 mumol . min-1 . 100 g-1) and TUDC (0.6 mumol . min-1 . 100 g-1) resulted in drastic (8- to 20-fold) decreases in excretion of these enzymes and albumin compared with respective values in rats infused with TCDC alone. Similar preventive effects were observed with the addition of TUDC to the infusion of TC (1.2 mumol . min-1 . 100 g-1). These results suggest that the hepatic cytotoxic effects of TC and TCDC can be prevented by the simultaneous infusion of TUDC in rats.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984943     DOI: 10.1152/ajpgi.1985.248.4.G407

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

1.  Disorder of bile acid metabolism in children with short bowel syndrome.

Authors:  N Ohkohchi; T Andoh; U Izumi; Y Igarashi; R Ohi
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

Review 2.  [Ursodeoxycholic acid--a new therapy concept in cholestatic liver diseases].

Authors:  R Raedsch; A Stiehl
Journal:  Klin Wochenschr       Date:  1989-02-15

3.  A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis.

Authors:  H Oka; G Toda; Y Ikeda; N Hashimoto; Y Hasumura; T Kamimura; Y Ohta; T Tsuji; N Hattori; T Namihisa
Journal:  Gastroenterol Jpn       Date:  1990-12

4.  The ursodeoxycholic acid story in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; T C Northfield
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

Review 5.  Ursodeoxycholic acid treatment of vanishing bile duct syndromes.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

6.  Effect of lecithin on the release of 5'-nucleotidase from liver plasma membrane of rat by bile acids.

Authors:  M Nokubo
Journal:  Lipids       Date:  1987-01       Impact factor: 1.880

7.  Protective effect of tauroursodeoxycholate against chenodeoxycholate-induced damage to cultured rabbit gastric cells.

Authors:  S Ota; H Tsukahara; A Terano; Y Hata; H Hiraishi; H Mutoh; T Sugimoto
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

8.  Tauroursodeoxycholic acid protects cholestasis in rat reperfused livers: its roles in hepatic calcium mobilization.

Authors:  T Ono; K Imai; H Kohno; M Uchida; Y Takemoto; D K Dhar; N Nagasue
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

9.  Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice.

Authors:  Jae-Seong Yang; Jin Taek Kim; Jouhyun Jeon; Ho Sun Park; Gyeong Hoon Kang; Kyong Soo Park; Hong Kyu Lee; Sanguk Kim; Young Min Cho
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

10.  Luminal bile regulates cholecystokinin release in conscious rats.

Authors:  R Nakamura; K Miyasaka; Y Kuyama; K Kitani
Journal:  Dig Dis Sci       Date:  1990-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.